Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02129322

Enrollment

Registered

2014-05-02

Start date

2015-07-31

Completion date

2019-12-31

Last updated

2021-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation

Interventions

DRUGSorafenib

DRUGS-1

DRUGOxaliplatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* hepatocellular carcinoma after liver transplantation * Major organ (heart, lung and brain) function was normal

Exclusion criteria

* Any active infectious process * The presence of clinically confirmed extrahepatic metastasis * Postoperative dysfunction of any organ

Design outcomes

Primary

Measure	Time frame	Description
Time to Recurrence (TTR)	within five years after liver transplantation	Time to Recurrence

Secondary

Measure	Time frame	Description
Overall survival (OS)	within the five years after liver transplantation	Overall survival

Other

Measure	Time frame	Description
Circulative tumor cell (CTC) level change	within one year after liver transplantation	Circulative tumor cell

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026